Could Low-Risk Breast Cancer Patients Benefit From Shorter Trastuzumab Treatment?

A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.

Source: CancerNetwork - October 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news